What are the two late-stage cancer drugs GSK acquired from Nuvalent, and what is their regulatory and commercial status?

The two late-stage drugs acquired are zidesamtinib and neladalkib, both next-generation treatments for non-small cell lung cancer currently under review by the U.S. Food and Drug Administration, with decisions expected in September and November; if approved, they are expected to launch later this year and could each generate several billion dollars in annual revenue as multi-blockbuster therapies targeting specific lung cancer mutations with improved tolerability and quality of life.

Why does GSK describe the Nuvalent acquisition as its biggest ever, and how does it fit into CEO Luke Miels’ strategic direction?

GSK states the $10.6bn Nuvalent deal is its largest acquisition ever — surpassing even its 2014 asset swap with Novartis (valued at $21bn but involving offsetting divestments) — and marks a major acceleration of Miels’ oncology-focused strategy, following his January $2.2bn acquisition of RAPT; Miels called it a 'brick-by-brick' expansion, emphasizing the immediate sales growth potential, 2027 profit contribution, and platform value for further lung cancer development including the late-stage candidate Ris-Rez.

GSK Makes Biggest Ever Acquisition with $10.6bn for US Cancer Drug Firm

Jun 9, 2026

GSK acquired US cancer firm Nuvalent for $10.6bn in its largest deal since 2014. The purchase adds two late-stage lung cancer drugs to GSK's pipeline, pending FDA approval later this year.

theguardian

2026-06-08

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports

2026-06-08

GSK Boosts Lung Cancer Portfolio with $10.6 Billion Nuvalent Takeover

2026-06-09

GSK to buy cancer drug developer Nuvalent for $10.6 billion

2026-06-09

US Stock Futures Rise as Chip Stocks Extend Gains; Oil Prices Drop on Ceasefire Hopes

2026-06-09

GSK Makes Biggest Ever Acquisition with $10.6bn for US Cancer Drug Firm